Keeping up with peptide regulations can feel like trying to read a map in a hurricane. One day a compound is everywhere, and the next, the FDA is raising a red flag.
We have pulled the latest data to help you understand what is happening with some of the most talked-about options. This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.
What is going on with BPC-157 and KPV?
If you have been following bpc-157, you know the rules have been shifting. As of September 2026, the FDA has identified potential safety concerns including immunogenicity (your immune system reacting to the peptide), impurities, and a lack of human safety info.
Here is the quick timeline for these two:
- BPC-157: Reviewed by the Pharmacy Compounding Advisory Committee in July 2026. It is currently not listed on the 503B Bulks List, which is a list of ingredients allowed for large-scale compounding.
- KPV: After being removed from Category 2 when a nomination was withdrawn, it was also reviewed by the advisory committee in July 2026.
The latest on Semaglutide shortages
The wild west of semaglutide compounding is changing because the national shortage has ended. This means the FDA is stepping back on the "enforcement discretion" that allowed for more flexible compounding.
Important safety notes for Semaglutide:
- Salt Forms: The FDA stated that semaglutide sodium and semaglutide acetate are not the same as the approved drug and has not identified a lawful basis for using them.
- Side Effects: Strong signals for nausea, vomiting, and delayed gastric emptying are already in the label.
- New Warnings: Emerging signals for pulmonary aspiration (fluid in the lungs) during anesthesia were added to labels in 2025. There is also an emerging signal for NAION, a serious eye condition, which was under EMA review as of January 2025.
Why are some peptides in Category 2?
When the FDA puts a substance in "Category 2," they are essentially saying, "Wait, we have safety concerns." Several popular compounds were placed here in September 2023:
- Melanotan II: Flagged for multiple serious adverse events.
- GHRP-2 and GHRP-6: Both flagged for immunogenicity concerns.
- LL-37: Listed due to general safety concerns.
- MK-677: Though not a peptide, it was placed in Category 2 in both 2022 and 2023.
How to move forward
Regulatory status is a great one to bring up with your doctor. You can find peptide-experienced physicians in our Find a Doctor directory.
If you are looking for a peptide doctor who stays current on these FDA shifts, checking the peptide therapy near me map is a smart first step. Regulations change fast, but your safety should always come first.
Referenced Peptides
This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.